Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase

Leuk Lymphoma. 2016;57(1):219-22. doi: 10.3109/10428194.2015.1045899. Epub 2015 Jul 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Bone Marrow / pathology
  • Dasatinib / administration & dosage*
  • Humans
  • Leukemia, Myeloid, Accelerated Phase / drug therapy*
  • Leukemia, Myeloid, Accelerated Phase / pathology*
  • Male
  • Middle Aged
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / pathology*
  • Protein Kinase Inhibitors / administration & dosage*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Dasatinib